Immunic, Inc. revealed new data from the Phase 2 CALLIPER trial showing that vidofludimus calcium, an investigational drug for progressive multiple sclerosis (MS), maintains favorable disability outcomes through 48 weeks of treatment with low discontinuation rates. The data, presented at MSToronto2026, also highlight the drug's neuroprotective effects linked to Nurr1 activation and its potential to reduce Epstein-Barr virus-related immune activity, which may improve cognitive function in MS patients. These findings support further development of vidofludimus calcium, with Phase 3 trials ongoing and additional studies planned for progressive MS later in 2026.
Immunic's new clinical data on vidofludimus calcium is the subject, with Pluang's Health sector market data providing context. As of Oct 07, 2026 19:12 WIB, out of 100 priced Health-sector US stocks tradable on Pluang, 44 rose and 50 fell today. Notable movers include MESO at USD 13.93 with a 1-day change of +2.35%, DHR at USD 220.38 up +2.24%, and TXG at USD 79.00 down -2.06%, with TXG showing a Pluang order activity of 46% Sell / 54% Buy. The most notable figure is MESO's typical hold time on Pluang of 14 Days.
Arthur J. Gallagher expects about 6% organic growth in Q3, driven by strong client retention and new business despite easing property insurance pricing. Cantor Fitzgerald lowered its price target to $280, below the $288 average from 19 analysts who m...
Needham raised Zscaler's price target to $255, citing strong demand for AI-related cybersecurity solutions. Zscaler aims to exceed $8 billion in annual recurring revenue by fiscal 2031, driven by increasing needs to protect against AI-powered cyberat...
Barclays has lowered its price target for Netflix shares from $80 to $70 due to concerns over slower revenue growth and rising content costs, especially for live programming. Despite Netflix's large subscriber base of 325 million, the company faces p...
Barclays has increased its price target for MetLife stock to $111 from $97, indicating potential upside as shares currently trade near $97.16. MetLife also declared a fourth-quarter 2026 dividend of $0.59 per common share, payable on December 8, 2026...
Nasdaq is enhancing its Calypso platform with agentic AI to improve trading and risk management, addressing manual post-trade tasks in financial services. Its Financial Technology unit saw 16% revenue growth and added numerous new clients, driven by ...
